Holen Sie sich die Stockscreener-App
9.7995
1.48%
-0.1305
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLDB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$9.93
Offen:
$9.77
24-Stunden-Volumen:
102.40K
Relative Volume:
0.07
Marktkapitalisierung:
$1.05B
Einnahmen:
$14.79M
Nettoeinkommen (Verlust:
$-191.78M
KGV:
-5.0344
EPS:
-1.9465
Netto-Cashflow:
$-172.86M
1W Leistung:
-4.88%
1M Leistung:
+16.60%
6M Leistung:
+21.98%
1J Leistung:
+95.66%
1-Tages-Spanne:
$9.65
$9.95
1-Wochen-Bereich:
$9.58
$10.48
52-Wochen-Spanne:
$3.79
$11.45
Solid Biosciences Inc Stock (SLDB) Company Profile
Firmenname
Solid Biosciences Inc
Sektor
Branche
Telefon
617-337-4680
Adresse
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
9.81 | 1.06B | 14.79M | -191.78M | -172.86M | -1.9465 |
VRTX
Vertex Pharmaceuticals Inc
|
522.83 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.17 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.20 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.32 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.18 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-20 | Eingeleitet | Guggenheim | Buy |
| 2025-12-04 | Eingeleitet | Needham | Buy |
| 2025-06-26 | Eingeleitet | Citigroup | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-13 | Eingeleitet | Wedbush | Outperform |
| 2024-12-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-15 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-06-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-03-28 | Eingeleitet | William Blair | Outperform |
| 2024-03-15 | Eingeleitet | Citigroup | Buy |
| 2024-03-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-07-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-05-27 | Eingeleitet | Jefferies | Buy |
| 2021-03-16 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-11 | Eingeleitet | Evercore ISI | Outperform |
| 2019-08-29 | Herabstufung | Citigroup | Neutral → Sell |
| 2019-08-19 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | Herabstufung | Goldman | Neutral → Sell |
| 2019-02-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-02-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | Eingeleitet | Citigroup | Sell |
| 2018-09-06 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Solid Biosciences Inc Aktie (SLDB) Neueste Nachrichten
Solid Biosciences Stock Price Forecast. Should You Buy SLDB? - StockInvest.us
Solid Biosciences LLC (NASDAQ: SLDB) Share Price, SLDB Stock News, SLDB Share Price & Updates - Kalkine
Solid Biosciences Insiders Sell US$823k Of Stock, Possibly Signalling Caution - simplywall.st
Solid Biosciences to Participate at Upcoming Investor Conferences - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), LeonaBio (LONA) and Solid Biosciences (SLDB) - The Globe and Mail
Cantor raises Solid Biosciences stock price target on gene therapy - Investing.com
Cantor raises Solid Biosciences stock price target on gene therapy By Investing.com - Investing.com Canada
Cantor Fitzgerald Maintains Solid Biosciences(SLDB.US) With Buy Rating, Raises Target Price to $26 - Moomoo
Solid Biosciences Inc (SLDB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SLDB Maintained by Truist Securities -- Price Target Raised to $20 - GuruFocus
Solid Biosciences (NASDAQ:SLDB) Earns Buy Rating from Analysts at Truist Financial - MarketBeat
Solid Biosciences (NASDAQ:SLDB) Stock Price Down 6.7%Time to Sell? - MarketBeat
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Solid Biosciences Inc. brings patient advocates to FA panel at GMP Lab - Traders Union
Perceptive Advisors (NASDAQ: SLDB) details 11.2% beneficial stake and warrant limits - Stock Titan
Solid Biosciences (SLDB): Vestal Point Capital discloses 4.8% ownership, including warrant shares - Stock Titan
Solid Biosciences (SLDB) Holds Steady Near $9.09 as Gene Therapy Sector Watches Key LevelsVolume Weighted Price - vinanet.vn
HC Wainwright Has Positive Estimate for SLDB Q3 Earnings - MarketBeat
Form 8K Solid Biosciences LLC For: 6 August By Investing.com - Investing.com Nigeria
J.P. Morgan Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Dimensional Fund Advisors LP Acquires 277,051 Shares of Solid Biosciences Inc. $SLDB - MarketBeat
Solid Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Citizens reiterates Solid Biosciences stock rating on pipeline progress By Investing.com - Investing.com Nigeria
Citizens reiterates Solid Biosciences stock rating on pipeline progress - Investing.com
Solid Biosciences (NASDAQ:SLDB) Posts Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
Solid Biosciences Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Solid Biosciences Inc. Stock 12‑Month Price Target Cut to $17.64, Implies 102% Upside - TradingView
Solid Biosciences Inc (SLDB) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Solid Biosciences files prospectus for up to $200 million at-the-market stock offering - Bitget
Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Solid Biosciences (SLDB) Eyes Key Clinical Milestones Amid High Valuation on Price-to-Sales Basis - GuruFocus
Solid Biosciences files prospectus supplement for up to $200 million stock offering - Investing.com Canada
Solid Biosciences (NASDAQ: SLDB) sets $200M stock sale capacity - Stock Titan
Solid Biosciences Q2 net loss widens on higher R&D costs - TradingView
Solid Biosciences Inc. Q2 2026: Revenue $0 Net loss $(54.8M), EPS $(0.38) — 10-Q Summary - TradingView
FMR LLC and Abigail Johnson (SLDB) disclose 7% beneficial stake in Solid Biosciences - Stock Titan
BlackRock, Inc. Expands Solid Biosciences (SLDB) Stake with Stra - GuruFocus
Solid Biosciences (SLDB) Expected to Release Quarterly Earnings on Tuesday - MarketBeat
Janus Henderson Group PLC Acquires Shares of 4,010,695 Solid Biosciences Inc. $SLDB - MarketBeat
SLDB|Solid Biosciences Inc|Price:8.080|Chg%:+0.020 - TradingKey
BlackRock (SLDB holder) discloses 6.5% Solid Biosciences stake in Schedule 13G - Stock Titan
Solid Biosciences Inc. $SLDB Shares Purchased by Ally Bridge Group NY LLC - MarketBeat
SLDB|Solid Biosciences Inc|Price:7.830|Chg%:-0.150 - TradingKey
Solid Biosciences Inc (SLDB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Solid Biosciences Inc (SLDB) Income Statement - TradingKey
Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Solid Biosciences Inc (SLDB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Solid Biosciences Inc (SLDB) Cash Flow - TradingKey
Solid Biosciences Inc (SLDB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Solid Biosciences (SLDB) Proxy filing Summary - Quartr
SLDB stock trades around recent lows as Solid Biosciences updates gene therapy pipeline - Ad-hoc-news.de
Finanzdaten der Solid Biosciences Inc-Aktie (SLDB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):